Baltimore, Maryland – Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors. In their study published Feb. 3 in Nature Communications, the team,...
Latest News
Baltimore, Maryland – A gene associated with colorectal cancer appears to also play a role in the development of other solid tumors, according to a study of over 350,000 patient biopsy samples conducted by researchers at the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and Foundation...
CHICAGO, Ill. – Skeletal muscle loss is a risk factor for developing dementia, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). Skeletal muscles make up about one-third of a person’s total body mass. They are connected to the bones...
Johns Hopkins Medicine (JHM) has been designated a National Organization for Rare Disorders (NORD) Rare Disease Center of Excellence. The newly established designation recognizes centers who are leaders in the diagnosis and care of people with rare diseases. JHM shares the recognition with the Kennedy Krieger Institute. Each year, clinicians...
SPRING HOUSE, Pa. — Johnson & Johnson today announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2 DAHLIAS study of nipocalimab in adults with Sjögren’s disease (SjD). Nipocalimab has demonstrated clinical effect in...
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer RARITAN, N.J. — Johnson...
HORSHAM, PA. — Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TECVAYLI® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma (RRMM) who have achieved and...
ORLANDO, Fla. — Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in...
SPRING HOUSE, Pa. — Johnson & Johnson Family of Companies today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for nipocalimab for the treatment of alloimmunizeda pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab is currently...
Boston –The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders. “Our family feels incredibly lucky to have...